METHODS: Patients received RES 3mg/kg [IV] (Q4W) or PBO for 52 weeks. In this posthoc analysis, individual ACQ-5 questions were assessed for change in mean score and change in proportion of patients with ≥moderate severity (score ≥3), at week 52 versus baseline.
RESULTS: Compared to PBO (n=475), RES (n=477) resulted in improvement in Q1 (nighttime awakenings [NA]) by -0.3, Q2 (morning symptoms [MS]) by -0.5, Q3 (activity limitation [AL]) by -0.3, Q4 (shortness of breath [SOB]) by -0.3, and Q5 (wheeze) by -0.4 (all p-values < 0.01). At baseline, 36% of patients had NA ≥ several times during the past week, decreased to 9% vs 13% in the RES and PBO groups, respectively, at week 52. At least moderate MS decreased from 60% at baseline to 13% and 22%, respectively. At least moderate AL decreased from 55% at baseline to 16% and 24%, respectively. At least moderate SOB decreased from 62% at baseline to 17% and 25%, respectively. At least moderate wheeze decreased from 55% at baseline to 13% and 23%, respectively.
CONCLUSIONS: In this asthma population with a high proportion of symptomatic patients at baseline, RES consistently improved all ACQ symptom question scores at 52-weeks and improved the proportion of patients with ≥ moderate symptoms.